Enveric Biosciences (ENVB)

• Market cap: $2.61M
• 1 day: 1.08%
• 5 days: -6%
• 1 month: -20%
• 3 months: -49.46%
• 6 months: -76.17%
• Year to date: -48.77%
• 1 year: -90.21%
• 5 years: -99.99%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

Employees: 6